Yusuf Roohani

Chevron down

Accelerating High Throughput Drug Discovery Using Deep Learning

Image-based high content screening is a well-established method for discovering new compounds at high throughput using their phenotypic signatures. Current processing of these imaging assays relies primarily on tedious and often subjective manual feature extraction requiring specialized skills. We've explored the application of deep convolutional neural networks to address these concerns. Beyond algorithmic hurdles, we faced challenges around building robust production-level models as well as integrating within a pharmaceutical context. This talk will discuss our approach towards building and industrializing deep learning based image analysis workflows within the early phases of drug discovery research.

Yusuf works as a data scientist in drug discovery research at GlaxoSmithKline in Cambridge, MA. Currently, his main focus is on putting together a computer vision platform for early stage drug discovery with broad usability across use cases and imaging domains. He also has previous experience within the areas of compound screening and biomarker identification as well as in building systems that fit a healthcare context. Yusuf was previously employed at Merrimack Pharmaceuticals and received his M.S. from Carnegie Mellon in 2015.

Buttontwitter Buttonlinkedin

As Featured In

Original
Original
Original
Original
Original
Original

Partners & Attendees

Intel.001
Nvidia.001
Ibm watson health 3.001
Acc1.001
Rbc research.001
Twentybn.001
Mit tech review.001
Kd nuggets.001
Facebook.001
Graphcoreai.001
Maluuba 2017.001
Forbes.001
This website uses cookies to ensure you get the best experience. Learn more